Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ALXN2220 in transthyretin amyloid cardiomyopathy
2023-506669-70-00Phase 3Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing ALXN2220 with Placebo (2 arms). Primary endpoint: Total occurrence of all-cause mortality and cardiovascular clinical events during the blinded treatment period. Planned start Apr 2024; status: authorised.
02
Drugs
cliramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2023-506669-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506669-70-00.